Generex Biotechnology (GNBTQ) 10-K2012 FY Annual report

Filed: 15 Oct 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adequacy, andControlled, andItem, arose, arrive, asserted, AtJuly, attorney, augment, Biopharma, Brazil, captionChange, category, circumvention, closure, conditionally, condominium, considersall, detinue, deviate, disgorged, disgorgement, divert, dormant, Eagleattended, eleven, entitledLiquid, excellent, extremely, Fellowshasserved, Frameworkissued, fraud, Galena, headingFinancial, Henry, HJF, ininventory, inItem, inNote, inPart, inPhase, Jackson, Jul, junior, lack, minimisnumber, nineteen, ourGenerex, overriding, pathway, promising, ratchet, refinancing, refrain, remediate, remediation, remedy, renegotiated, repurchase, rescission, Richmond, SeeNote, SeePart, segregation, standardsrequire, Statementsincluded, subheadingsFinancing, suggest, tabulated, thisPart, toa, underItem, underPart, variable, visit, West

Removed: abdominal, Academy, accrual, add, adjust, advisor, age, ahead, aid, Algorithm, alliance, amenable, amounting, anxiety, baltic, Beijing, biology, Biovail, bitter, bloating, bottle, branch, breakthrough, building, Bush, Butler, capacity, Centre, Cephalon, chaired, circulatory, collect, collectability, commonly, companion, Connaught, conventional, coordination, council, cravenx, Dalhousie, Danish, Danziger, Daopei, Davidson, declaratory, delayed, demonstrable, Department, diarrhea, DIK, Dimethaid, distinguished, distributed, doubtful, drop, Drugmart, DURAGESIC, duration, easily, education, endocrine, energy, ensue, episode, establishment, execution, expand, experimentalist, expression, failed, fast, FENTORA, Fertin, floor, foot, gas, Genpharm, George, GMP, Governor, Harold, hindered, Hochman, hundred, immunology, improve, improvement, inaction, injunctive, instituted, instructor, Insubstantial, intake, intensity, Intensive, intent, interference, introduction, invasive, Investigatory, irradiation, Italy, Jaime, Japan, Jarnitskii, Keck, Kinney, Latin, lethal, liaison, McGill, McKesson, MD, medicated, medication, medium, Meijer, Merieux, MHC, Midwestern, Minzhen, moderate, modification, modifying, Moscow, mutual, myeloid, nausea, network, obesity, officially, operative, OXYCONTIN, packaging, Perry, persistent, pioneering, post, postoperative, Powell, precise, procedure, procuring, promissory, prospectively, prove, Purdue, reached, Regent, regimen, relinquish, retrospectively, Rexall, Rick, Rifkin, RNA, RNAi, Rome, royalty, San, Sandoz, SAP, satisfactory, scenario, Scott, Shanghai, Shoppe, show, silence, sixty, Slava, SMO, solubilization, Southwestern, staple, stomach, storing, sublease, suited, Syria, taste, Tech, Tennessee, theoretical, tool, transfected, transition, treating, unclear, uncollectible, unsuitable, USA, usable, utilized, vector, volatile, vomiting, waive, White, Winthrop, Xu, younger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GNBTQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements of Generex Biotechnology Corporation on Form S-3, as amended (File No. 333-150562, 333-67118, 333-106519, 333-110493, 333-112891, 333-117822, 333-121309, 333-126624, 333-128328, 333-131430, 333-135284, and 333-164591), Form S-1, as amended (File No. 333-180170 and File No. 333-183865) and Form S-8, as amended (File No. 333-55072, 333-66654, 333-88026, and 333-145412), of our reports dated October 15, 2012 relating to the consolidated financial statements of the Company and the effectiveness of the Company’s internal control over financial reporting for the year ended July 31, 2012 included in the Annual Report of Generex Biotechnology Corporation on Form 10-K for the year ended July 31, 2012. Our report relating to the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern and our report on internal controls over financial reporting expressed an adverse opinion.

/s/ MSCM LLP

Toronto, Canada

October 15, 2012